Registration - In-house Corporation

AstraZeneca Canada Inc. / Kiersten Combs, President

Registration Information

In-house Corporation name: AstraZeneca Canada Inc.
Responsible Officer Name: Kiersten Combs, President
Responsible Officer Change History
Initial registration start date: 2007-03-08
Registration status: Active
Registration Number: 949884-15042

Associated Communications

Total Number of Communication Reports: 112

Monthly communication reports in the last 6 months: 9

Version 25 of 54 (2015-08-21 to 2015-12-21)

Registration versions:

Version 25 of 54 (2015-08-21 to 2015-12-21)

Lobbying Information

Subject Matters

Aboriginal Affairs
Constitutional Issues
Consumer Issues
Environment
Health
Industry
Intellectual Property
Internal Trade
International Development
International Relations
International Trade
Justice and Law Enforcement
Regional Development
Research and Development
Science and Technology
Taxation and Finance

Subject Matter Details

Policies or Program

Canada's Access to Medicines Regime (CAMR) with regard to ensuring that the program allows for the delivery of timely access to needed medicines to the developing world supported by a business climate in Canada that continues to encourage research into further treatment and prevention of disease.
Canada's Food and Consumer Safety Action Plan with regard to ensuring that patient safety is a priority in a modern, efficient and internationally harmonized regulatory system that must be evidence-based, efficient and continuous while supporting timely access to innovative medicines and vaccines for Canadians, protecting intellectual property rights and preserving competitive research advantage.
Cost Recovery Initiative, ensuring a framework where user fees adequately fund a safe and efficient review process.
National Pharmaceutical Strategy (NPS) with regard to ensuring development or implementation of any policies or programs include consultations with all affected stakeholders and focus on bettering access to medicines for Canadians.
Patented Medicines Price Review Board (PMPRB) with regard to ensuring that PMPRB Guidelines, Policies and Procedures reflect PMPRB mandate to ensure that prices charged for patented medicines in Canada are not excessive and that potential changes consider impact to the pharmaceutical industry.
Public policy issues related to Health Canada's review of NCE
Science and Technology (S&T) Strategy with regard to ensuring that the implementation of that strategy encourages a public policy environment that attracts business investment in innovation and enhances the ability of Canadian industry to compete internationally.
Scientific Research and Experimental Development (SR&ED) Tax Incentive Program with regard to expansion of eligible expenditures to recognize the impact on innovation and the research and development (R&D) investment by the pharmaceutical industry in Canada.
The Canada-European Union Comprehensive Economic and Trade Agreement (CETA) negotiations with respect to biopharmaceuticals and intellectual property right protection.

Policies or Program, Regulation

Blueprint for Renewal with regard to ensuring a modern, efficient and internationally harmonized regulatory system that must be evidence-based, efficient and continuous while supporting timely access to innovative medicines and vaccines for Canadians, protecting intellectual property rights and preserving competitive research advantage.

Regulation

Patented Medicine Prices Review Board (PMPRB) with regard to ensuring guidelines also provide incentives for innovation through research and development in addition to PMPRB mandate of protection from excessive prices.
Patented Medicines (Notice Of Compliance) Regulations with regard to ensuring that Canada's intellectual property (IP) laws and regulations are internationally competitive and continue to provide a stable and predictable business environment to encourage continued pharmaceutical investment in Canada.

Communication Techniques

Written communication
Oral communication
Grass-roots communication

Government Institutions

Aboriginal Affairs and Northern Development Canada
Agriculture and Agri-Food Canada (AAFC)
Atlantic Canada Opportunities Agency (ACOA)
Canada Revenue Agency (CRA)
Canadian Institutes of Health Research (CIHR)
Canadian International Trade Tribunal (CITT)
Competition Bureau Canada (COBU)
Environment Canada
Federal Office of Regional Development – Quebec (FORD[Q])
Finance Canada (FIN)
Foreign Affairs, Trade and Development Canada
Health Canada (HC)
House of Commons
Industry Canada
Members of the House of Commons
National Defence (DND)
National Research Council (NRC)
Natural Sciences and Engineering Research Council (NSERC)
Patented Medicine Prices Review Board (PMPRB)
Prime Minister's Office (PMO)
Privy Council Office (PCO)
Public Health Agency of Canada (PHAC)
Royal Canadian Mounted Police (RCMP)
Senate of Canada
Treasury Board Of Canada Secretariat (TBS)
Veterans Affairs Canada (VAC)
Western Economic Diversification Canada (WD)

In-house Corporation Details

Description of activities

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. AstraZeneca’s Canadian headquarters are located in Mississauga, Ontario. For more information, please visit the company’s website at www.astrazeneca.ca.

Responsible officer name and position during the period of this registration

Ed Dybka, President and Chief Executive Officer

Government funding

No government funding was received during the last completed financial year.

In-house Corporation Contact Information

Address:
1004 Middlegate Road
Mississauga, ON L4Y 1M4
Canada

Telephone number: 905-804-5840

Parent Company Information

AstraZeneca PLC
- 2 Kingdom Street
  London W26BD
  United Kingdom

Subsidiary Beneficiary Information

AstraZeneca Canada Inc. does not have any subsidiaries that could have a direct interest in the outcome of the undertaking

Lobbyists Details

List of Senior Officers whose lobbying activities represent less than 20% of their Duties

Ed Dybka, President & CEO | No public offices held
Brian Maloney, Director, Government Affairs, Stakeholders & Corporate Responsibility | No public offices held
Neil Maresky, Vice President, Scientific Affairs | No public offices held
Lisa Marsden, Vice President, Market Access & Government Affairs | No public offices held
Crawford Wright, Chief Compliance and Privacy Officer | No public offices held

List of Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties

Tara Bingham, Senior Manager, Government Affairs | Public offices held
Claudia Neuber, Director, Pricing & Contracting | No public offices held

AstraZeneca Canada Inc.

The following names have been used on or after July 2, 2008

The following names have been used on or after July 2, 2008
Name	From	To
AstraZeneca Canada Inc.	2008-07-31	current

The following names have been used before July 2, 2008

AstraZeneca Canada Inc.

AstraZeneca Canada Inc.

Responsible Officer History
Responsible Officer Name	From (YYYY-MM-DD)	To (YYYY-MM-DD)
Kiersten Combs	2021-09-01	Current
Jane Chung	2019-11-01	2021-09-01
Daniel Smedley	2019-08-01	2019-11-01
Jamie Freedman	2017-11-28	2019-08-01
Ed Dybka	2015-01-02	2017-11-28
Elaine Campbell	2012-01-09	2015-01-02
Marion McCourt	2010-04-12	2012-01-09
Mark Jones	2007-03-08	2010-04-12

Kiersten Combs, President (Corporation)

Learn more...

Registrants are required to submit a monthly communication report for each oral and arranged communication with a designated public office holder. The name of the most senior paid officer (i.e. the registrant) will appear on all in-house monthly communication reports, whether or not he/she participated in the communication.

Note: Monthly Communication Reports are due on the 15^th day of each month for communications that took place in the previous month.

Results below are sorted by posted date, beginning with the most recent.

Results 1-112 of 112

AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Mark Kachuk, Special Assistant | Prime Minister's Office (PMO)
- Udita Samuel, Policy Advisor | Prime Minister's Office (PMO)
- Ben Chin, Policy Advisor | Prime Minister's Office (PMO)
Subject Matter of the communication: Health, Research and Development
Communication date: 2023-02-01
Posted date: 2023-03-17
Communication number: 15042-560351 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Shanzae Khan, Policy Advisor | Ministry of Health | Health Canada (HC)
- Sadenga Yeba, Deputy Director of Policy | Ministry of Health | Health Canada (HC)
- Jean-Sebastien Bock, Director of Policy | Office of the Minister of Health | Health Canada (HC)
Subject Matter of the communication: Research and Development, Economic Development
Communication date: 2023-01-31
Posted date: 2023-02-15
Communication number: 15042-556377 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Craoline Menard, Manager | Innovation, Science and Economic Development Canada (ISED)
- Rodrigo Arancibia, Director for Innovation, Science and Economic Development | Innovation, Science and Economic Development Canada (ISED)
Subject Matter of the communication: Economic Development
Communication date: 2023-01-26
Posted date: 2023-02-15
Communication number: 15042-556376 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Sandenga Yeba, Senior Policy Advisor | Minister's Office | Health Canada (HC)
- Jean-Sebastien Bock, Director of Policy | Office of the Minister of Health | Health Canada (HC)
- Jean-Yves Duclos, Minister of Health | Health Canada (HC)
Subject Matter of the communication: Health, Economic Development
Communication date: 2022-12-22
Posted date: 2023-01-16
Communication number: 15042-553093 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Sandenga Yeba, Senior Policy Advisor | Minister's Office | Health Canada (HC)
Subject Matter of the communication: Health, Research and Development
Communication date: 2022-11-18
Posted date: 2022-12-16
Communication number: 15042-552423 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Yash Nanda, Policy Advisor | Deputy Prime Minister's office | Finance Canada (FIN)
Subject Matter of the communication: Industry
Communication date: 2022-11-11
Posted date: 2022-12-15
Communication number: 15042-549834 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Michelle Boudreau, Executive Director | Office of Pharmaceutical Management Strategies | Health Canada (HC)
Subject Matter of the communication: Industry
Communication date: 2022-11-04
Posted date: 2022-12-15
Communication number: 15042-549833 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Darryl Patterson, Director General | Innovation, Science and Economic Development Canada (ISED)
- Kasondra White, Director General | Innovation, Science and Economic Development Canada (ISED)
Subject Matter of the communication: Industry
Communication date: 2022-10-27
Posted date: 2022-12-12
Communication number: 15042-549835 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Michelle Mujoomdar, Director, Specialty Pharmaceuticals | Strategic Policy Branch | Health Canada (HC)
- Michelle Boudreau, Executive Director, Office of Pharmaceuticals Management Strategies | Strategic Policy Branch | Health Canada (HC)
Subject Matter of the communication: Health, Research and Development
Communication date: 2022-09-28
Posted date: 2022-10-15
Communication number: 15042-543621 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Simon Kennedy, Deputy Minister | Innovation, Science and Economic Development Canada (ISED)
Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade, Science and Technology
Communication date: 2022-06-28
Posted date: 2022-07-15
Communication number: 15042-537072 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Nancy Hamzawi, Federal Lead and Assistant Deputy Minister | COVID-19 Testing, Contact Tracing and Data Strategy Secretariat | Health Canada (HC)
- Stephen Lucas, Deputy Minister | Health Canada (HC)
Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade, Science and Technology
Communication date: 2022-06-27
Posted date: 2022-07-15
Communication number: 15042-537070 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Michelle Boudreau, Executive Director, Office of Pharmaceuticals Management Strategies | Strategic Policy Branch | Health Canada (HC)
Subject Matter of the communication: Health, Industry
Communication date: 2022-06-24
Posted date: 2022-07-15
Communication number: 15042-537377 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Sandenga Yeba, Senior Policy Advisor | Minister's Office | Health Canada (HC)
- Jean-Sebastien Bock, Director of Policy | Office of the Minister of Health | Health Canada (HC)
Subject Matter of the communication: Health
Communication date: 2022-06-21
Posted date: 2022-07-15
Communication number: 15042-537715 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Hilary Peirce, Senior Policy Advisor | Treasury Board Of Canada Secretariat (TBS)
Subject Matter of the communication: Health, Industry
Communication date: 2022-06-01
Posted date: 2022-07-15
Communication number: 15042-537376 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Sadenga Yeba, Senior Policy Advisor | Minister Duclos office | Health Canada (HC)
Subject Matter of the communication: Health
Communication date: 2022-03-17
Posted date: 2022-04-16
Communication number: 15042-527813 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Jean-Sébastien Bock, Director of Policy | Minister's Office | Health Canada (HC)
Subject Matter of the communication: Health
Communication date: 2022-01-26
Posted date: 2022-02-15
Communication number: 15042-522559 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Ed Fast, Member of Parliament | House of Commons
Subject Matter of the communication: Health, Industry, Science and Technology, Research and Development, Economic Development
Communication date: 2021-12-21
Posted date: 2022-01-15
Communication number: 15042-518830 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Kirsty Duncan, Member of Parliament | House of Commons
Subject Matter of the communication: Health, Industry, Science and Technology, Research and Development, Economic Development
Communication date: 2021-12-17
Posted date: 2022-01-15
Communication number: 15042-518828 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Martin Montreuil, Director | Public Services and Procurement Canada (PSPC)
- Mario Dicaire, Senior Manager | Procurement Services | Public Services and Procurement Canada (PSPC)
Subject Matter of the communication: Government Procurement
Communication date: 2021-12-14
Posted date: 2022-01-15
Communication number: 15042-519333 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Michael Mills, Assistant Deputy Minister | Public Services and Procurement Canada (PSPC)
- Milan Patel, Senior Manager | Vaccine Supply & Assurance | Public Services and Procurement Canada (PSPC)
Subject Matter of the communication: Health, Science and Technology
Communication date: 2021-12-13
Posted date: 2022-01-15
Communication number: 15042-519332 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Bersabel Ephrem, DIrector General | Public Health Agency of Canada (PHAC)
- Jacqueline Arthur, Assistant Executive Director | Public Health Agency of Canada (PHAC)
Subject Matter of the communication: Health
Communication date: 2021-12-03
Posted date: 2022-01-15
Communication number: 15042-519331 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Pierre Sabourin, Assistant Deputy Minister | Health Products and Foods Branch | Health Canada (HC)
- Eric Belair, Associate Assistant Deputy Minister | Strategic Policy Branch | Health Canada (HC)
- Nancy Hamzawi, Federal Lead and Assistant Deputy Minister | COVID-19 Testing, Contact Tracing and Data Strategy Secretariat | Health Canada (HC)
Subject Matter of the communication: Health, Industry
Communication date: 2021-12-03
Posted date: 2022-01-15
Communication number: 15042-519090 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Michelle Boudreau, Executive Director, Office of Pharmaceuticals Management Strategies | Strategic Policy Branch | Health Canada (HC)
- Lawrence Cheung, Director, Office of Pharmaceuticals Management Strategies | Strategic Policy Branch | Health Canada (HC)
Subject Matter of the communication: Health
Communication date: 2021-10-29
Posted date: 2021-11-15
Communication number: 15042-515244 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Joelle Paquette, Director General | Public Services and Procurement Canada (PSPC)
- Michael Mills, Acting Assistance Deputy Minister | Public Services and Procurement Canada (PSPC)
Subject Matter of the communication: Science and Technology
Communication date: 2021-10-13
Posted date: 2021-11-15
Communication number: 15042-515494 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- François-Philippe Champagne, Minister | Minister's Office | Innovation, Science and Economic Development Canada (ISED)
- Amanda Woodley, Policy Advisor | Minister's Office | Innovation, Science and Economic Development Canada (ISED)
Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
Communication date: 2021-04-29
Posted date: 2021-05-15
Communication number: 15042-503715 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Tamara Jansen, Member of Parliament | House of Commons
Subject Matter of the communication: Health, Science and Technology
Communication date: 2020-09-25
Posted date: 2020-10-15
Communication number: 15042-483387 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Michelle Rempel Garner, Member of Parliament | House of Commons
Subject Matter of the communication: Health
Communication date: 2020-09-16
Posted date: 2020-10-15
Communication number: 15042-483386 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Tamara Jansen, Member of Parliament | House of Commons
Subject Matter of the communication: Health, Industry, Research and Development
Communication date: 2020-07-08
Posted date: 2020-08-15
Communication number: 15042-479117 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Matt Jeneroux, Member of Parliament | House of Commons
Subject Matter of the communication: Health, Industry, Research and Development
Communication date: 2020-03-11
Posted date: 2020-04-16
Communication number: 15042-471269 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Steve Verheul, Assistant Deputy Minister | Trade and Policy Negotiations | Global Affairs Canada (GAC)
Subject Matter of the communication: International Trade
Communication date: 2020-01-16
Posted date: 2020-02-13
Communication number: 15042-464272 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Dan Albas, Member of Parliament | House of Commons
Subject Matter of the communication: Health, Industry, Research and Development
Communication date: 2019-06-05
Posted date: 2019-07-15
Communication number: 15042-457551 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Suzy McDonald, Assistant Deputy Minister, Federal-Provincial Relations and Social Policy | Finance Canada (FIN)
Subject Matter of the communication: Health, Industry, Science and Technology
Communication date: 2019-03-04
Posted date: 2019-04-15
Communication number: 15042-448813 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Karina Rolland-Sardana, Stakeholder Relations Advisor | House of Commons Party Officers | House of Commons
Subject Matter of the communication: Health, Industry, Intellectual Property, Science and Technology
Communication date: 2019-01-30
Posted date: 2019-12-13
Communication number: 15042-461617 (amended from 15042-445421) View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Marilyn Gladu, Member of Parliament | House of Commons
Subject Matter of the communication: Health, Industry, Research and Development
Communication date: 2018-12-03
Posted date: 2019-01-15
Communication number: 15042-443766 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Daniel Albas, Member of Parliament / Opposition Innovation, Science & Economic Development Critic | House of Commons
- John Knubley, Deputy Minister | Innovation, Science and Economic Development Canada (ISED)
- Lloyd Longfield, Member of Parliament / Member INDU Committee & Chair of Innovation and Technology Caucus | House of Commons
- Giancarlo Cairo, Chief of Staff for Minister ISED | Innovation, Science and Economic Development Canada (ISED)
- David Lametti, Member of Parliament / Parliamentary Secretary to the Minister of ISED | Innovation, Science and Economic Development Canada (ISED)
Subject Matter of the communication: Health, Industry, Research and Development
Communication date: 2018-10-23
Posted date: 2018-11-15
Communication number: 15042-436892 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Mathieu Bouchard, Senior Advisor | Prime Minister's Office (PMO)
- Rick Theis, Policy Advisor | Prime Minister's Office (PMO)
Subject Matter of the communication: Health, Research and Development, Economic Development
Communication date: 2018-07-12
Posted date: 2018-08-15
Communication number: 15042-432055 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- John Knubley, Deputy Minister | Innovation, Science and Economic Development Canada (ISED)
- David McFarlane, Director of Policy | Office of the Minister of Innovation, Science and Economic Development | Innovation, Science and Economic Development Canada (ISED)
Subject Matter of the communication: Health, Industry, Science and Technology, Research and Development, Economic Development
Communication date: 2018-06-05
Posted date: 2018-07-16
Communication number: 15042-431053 (amended from 15042-429373) View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Maxime Dea, Policy Advisor | Prime Minister's Office (PMO)
- Rick Theis, Policy Advisor | Prime Minister's Office (PMO)
Subject Matter of the communication: Health, Industry, Science and Technology, Research and Development, Economic Development
Communication date: 2018-05-31
Posted date: 2018-06-15
Communication number: 15042-429528 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Tom Kmiec, Member of Parliament | House of Commons
- Stephanie Kusie, Member of Parliament | House of Commons
- Earl Dreeshen, Member of Parliament | House of Commons
Subject Matter of the communication: Health, Industry, Research and Development
Communication date: 2018-04-17
Posted date: 2018-05-15
Communication number: 15042-425808 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Scott Brison, President | Treasury Board Of Canada Secretariat (TBS)
Subject Matter of the communication: Science and Technology, Research and Development
Communication date: 2018-04-04
Posted date: 2018-06-11
Communication number: 15042-427920 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Abby Hoffman, Assistant Deputy Minister - Strategic Policy | Health Canada (HC)
- Eric Dagenais, Assistant Deputy Minister | Innovation, Science and Economic Development Canada (ISED)
- Simon Kennedy, Deputy Minister | Health Canada (HC)
- John Knubley, Deputy Minister | Innovation, Science and Economic Development Canada (ISED)
- Gianluca Cairo, Chief of Staff | Innovation, Science and Economic Development Canada (ISED)
- David McFarlane, Director of Policy | Innovation, Science and Economic Development Canada (ISED)
- Genevieve Hinse, Chief of Staff | Health Canada (HC)
- Kathryn Nowers, Director of Policy | Health Canada (HC)
- Hilary Travis, Special Assitant (Policy) | Innovation, Science and Economic Development Canada (ISED)
Subject Matter of the communication: Health, Industry, Science and Technology
Communication date: 2018-04-03
Posted date: 2018-05-15
Communication number: 15042-425786 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Navdeep Bains, Minister of Innovation Science & Economic Development | Innovation, Science and Economic Development Canada (ISED)
- Javid Dharas, Policy Advisor | Office of the Minister of Innovation Science & Economic Development | Innovation, Science and Economic Development Canada (ISED)
Subject Matter of the communication: Health, Industry, Science and Technology, Research and Development, Economic Development
Communication date: 2018-03-20
Posted date: 2018-04-13
Communication number: 15042-423818 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Marilyn Gladu, Member of Parliament | House of Commons
Subject Matter of the communication: Health, Industry, Science and Technology, Research and Development
Communication date: 2018-03-08
Posted date: 2018-03-16
Communication number: 15042-422578 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Marilyn Gladu, Member of Parliament | House of Commons
Subject Matter of the communication: Health, Industry, Science and Technology, Research and Development
Communication date: 2018-02-08
Posted date: 2018-03-16
Communication number: 15042-422583 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Mathieu Bouchard, Senior Advisor | Prime Minister's Office (PMO)
- Maxine Dea, Policy Advisor | Prime Minister's Office (PMO)
Subject Matter of the communication: Health, Industry, Research and Development, Economic Development
Communication date: 2018-01-30
Posted date: 2018-02-15
Communication number: 15042-418915 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Peter Fonseca, Member of Parliament | House of Commons
Subject Matter of the communication: Health, Industry, Research and Development
Communication date: 2018-01-22
Posted date: 2018-03-16
Communication number: 15042-422584 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Sven Spengemann, MP | House of Commons
Subject Matter of the communication: Health, Research and Development, Economic Development
Communication date: 2017-12-18
Posted date: 2018-01-15
Communication number: 15042-418190 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Rob Oliphant, Member of Parliament | House of Commons
Subject Matter of the communication: Health, Intellectual Property, Research and Development
Communication date: 2017-11-15
Posted date: 2017-12-15
Communication number: 15042-416684 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Kendal Weber, Associate Assistant Deputy Minister | Health Products and Food Branch | Health Canada (HC)
- Abby Hoffman, Assistant Deputy Minister | Strategic Policy Branch | Health Canada (HC)
- Pierre Sabourin, Assistant Deputy Minister | Health Products and Food Branch | Health Canada (HC)
- Simon Kennedy, Deputy Minister | Deputy Minister's Office | Health Canada (HC)
Subject Matter of the communication: Health, Industry, Research and Development, Economic Development
Communication date: 2017-11-14
Posted date: 2018-07-20
Communication number: 15042-431460 (amended from 15042-431457) View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Maxime Dea, Policy Advisor | Prime Minister's Office (PMO)
Subject Matter of the communication: Health, Industry, Intellectual Property, Research and Development, Economic Development
Communication date: 2017-10-30
Posted date: 2017-11-15
Communication number: 15042-412632 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Kathryn Nowers, Policy Advisor | Health Canada (HC)
Subject Matter of the communication: Health, Industry, Intellectual Property, Research and Development, Economic Development
Communication date: 2017-10-30
Posted date: 2017-11-15
Communication number: 15042-412626 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Dean Allison, Member of Parliament | House of Commons
Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade, Research and Development
Communication date: 2017-09-28
Posted date: 2017-10-13
Communication number: 15042-409444 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- David McFarlane, Director of Policy | Office of the Minister of Innovation, Science and Economic Development | Innovation, Science and Economic Development Canada (ISED)
- Parvinder Sachdeva, Policy Advisor | Office of the Minister of Innovation, Science and Economic Development | Innovation, Science and Economic Development Canada (ISED)
Subject Matter of the communication: Health, Industry, Intellectual Property, Research and Development, Economic Development
Communication date: 2017-07-06
Posted date: 2017-08-15
Communication number: 15042-406861 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- David Lametti, Parliamentary Secretary to the Mininister of ISED | Innovation, Science and Economic Development Canada (ISED)
Subject Matter of the communication: Industry, Intellectual Property, International Trade
Communication date: 2017-06-22
Posted date: 2017-07-14
Communication number: 15042-405583 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Steve Verheul, Chief Trade Negotiator | Trade Agreements and Negotiations | Global Affairs Canada (GAC)
Subject Matter of the communication: Intellectual Property, International Trade
Communication date: 2017-06-22
Posted date: 2017-07-14
Communication number: 15042-405579 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Kelly Gillis, Associate Deputy Minister | Office of the Deputy Minister | Innovation, Science and Economic Development Canada (ISED)
- Corinne Guenette, Director, Life Sciences | Manufacturing and Life Sciences | Innovation, Science and Economic Development Canada (ISED)
Subject Matter of the communication: Industry, Research and Development, Economic Development
Communication date: 2017-06-19
Posted date: 2017-07-15
Communication number: 15042-404942 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Kirsty Duncan, Federal Minister of Science | Innovation, Science and Economic Development Canada (ISED)
Subject Matter of the communication: Science and Technology
Communication date: 2017-05-05
Posted date: 2017-06-15
Communication number: 15042-403452 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Steve Veheul, Chief Trade Negotiator | Trade Agreements and Negotiations | Global Affairs Canada (GAC)
- Francois-Philippe Champagne, Minister of International Trade | Global Affairs Canada (GAC)
- Ailish Campbell, Assistant Deputy Minister | Chief Trade Commissioner | Global Affairs Canada (GAC)
Subject Matter of the communication: Industry, Intellectual Property, International Trade
Communication date: 2017-04-10
Posted date: 2018-04-20
Communication number: 15042-424607 (amended from 15042-400539) View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Peter Harder, Senator | Senate of Canada
- Roy Rempel, Legislative Assistant | Office of the Leader of the Opposition in the Senat | Senate of Canada
Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
Communication date: 2017-03-01
Posted date: 2017-04-13
Communication number: 15042-398781 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Corinne Guenette, Director, Life Science Industries Directorate | Innovation Science and Economic Development | Innovation, Science and Economic Development Canada (ISED)
Subject Matter of the communication: Industry, Research and Development, Economic Development
Communication date: 2017-02-15
Posted date: 2017-03-15
Communication number: 15042-395231 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Peter Fonseca, Member of Parliament | House of Commons
Subject Matter of the communication: Health, Industry, Research and Development
Communication date: 2016-11-09
Posted date: 2016-12-15
Communication number: 15042-391240 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- David Lametti, Partliamentary Secretary | International Trade | Global Affairs Canada (GAC)
Subject Matter of the communication: Industry, Intellectual Property, Research and Development, Economic Development
Communication date: 2016-09-28
Posted date: 2016-10-14
Communication number: 15042-385474 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Simon Kennedy, Deputy Minister of Health | Health Canada (HC)
- Anil Arora, Assistant Deputy Minister | Health Products and Food Branch | Health Canada (HC)
Subject Matter of the communication: Health
Communication date: 2016-02-22
Posted date: 2016-03-16
Communication number: 15042-372974 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- John Pecman, Commissioner of Competition | Competition Bureau | Competition Bureau Canada (COBU)
Subject Matter of the communication: Consumer Issues, Health, Industry, Intellectual Property
Communication date: 2015-12-07
Posted date: 2016-01-12
Communication number: 15042-366365 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Anil Arora, Assistant Deputy Minister | Health Canada | Health Canada (HC)
Subject Matter of the communication: Health
Communication date: 2015-03-26
Posted date: 2015-04-15
Communication number: 15042-350667 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Richard Taylor, Deputy Commissioner of Competition | Civil Matters Brance | Competition Bureau Canada (COBU)
- Alan Gunderson, Coordinator | Economic Policy and Enforcement Branch | Competition Bureau Canada (COBU)
- Dave Warford, Competition Law Officer | Civil Matters Branch | Competition Bureau Canada (COBU)
- Kevin Rushton, Senior Competition Law Officer | Civil Matters Branch, Division A | Competition Bureau Canada (COBU)
- Marilyn Leblanc, Senior Competition Law Officer | Legislative and International Affairs Branch | Competition Bureau Canada (COBU)
- Guillaume Couillard, Major Case Director and Strategic Policy Advisor | Civil Matters Branch | Competition Bureau Canada (COBU)
- Martine Dagenais, Deputy Commission of Competition | Competition Bureau Canada (COBU)
- Roger Charland, Deputy Commission | Competition Bureau Canada (COBU)
Subject Matter of the communication: Industry
Communication date: 2014-02-28
Posted date: 2014-03-14
Communication number: 15042-319190 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Rob Merrifield, Member of Parliament | House of Commons
- Gerald Keddy, Parlimentary Secretary to the Minister of International Trade | Foreign Affairs and International Trade Canada (DFAITC)
Subject Matter of the communication: Intellectual Property, International Trade
Communication date: 2013-05-09
Posted date: 2013-06-15
Communication number: 15042-277316 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Christian Paradis, Minister of Industry | Industry Canada
- Sean O'Leary, Policy Adviser | Industry Canada
- Margaux Stastny, Communication Director | Industry Canada
Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
Communication date: 2012-08-27
Posted date: 2012-09-14
Communication number: 15042-236841 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Christian Paradis, Minister of Industry | Industry Canada
- Dr. Ailish Campbell, Director General | Manufacturing & Life Sciences | Industry Canada
- Mark Schaan, Direcrtor | Pharmaceutical Sector Directorate | Industry Canada
- Sean O'Leary, Policy Adviser | Industry Canada
- Diane L'Ecuyer, Director | Policy, Analysis & Intelligence | Industry Canada
- Denis Martel, Director | Patent Policy | Industry Canada
Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade, Science and Technology, Taxation and Finance, Research and Development
Communication date: 2012-08-09
Posted date: 2012-09-14
Communication number: 15042-236842 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Philip Jennings, Associate Assistant Deputy Minister | Industry Sector | Industry Canada
Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade, Science and Technology
Communication date: 2012-06-14
Posted date: 2012-07-16
Communication number: 15042-230757 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Alain Beaudet, President | Canadian Institutes of Health Research (CIHR)
Subject Matter of the communication: Health, Industry, Science and Technology
Communication date: 2012-06-07
Posted date: 2012-07-16
Communication number: 15042-230760 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Hon. Rob Merrifield, Chair of the Standing Committee on International Trade | House of Commons
Subject Matter of the communication: Industry, Intellectual Property, International Trade
Communication date: 2012-05-15
Posted date: 2012-06-15
Communication number: 15042-227308 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Mark Schaan, Director, Pharmaceutical Policy | Life Science Industry Branch | Industry Canada
- Julie Aubut, Senior Economist Policy, Analysis and Intelligence | 5 PLace Ville Marie | Industry Canada
Subject Matter of the communication: Research and Development
Communication date: 2012-03-27
Posted date: 2012-04-16
Communication number: 15042-219088 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Tom Wilson, Policy Analyst | Life Science Industry Branch | Industry Canada
- Marie Helene St Louis, Senior Economist and Branch Manager | Life Science Industry Branch | Industry Canada
Subject Matter of the communication: Research and Development
Communication date: 2012-03-27
Posted date: 2012-04-16
Communication number: 15042-219087 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Patrick Brown, Member of Parliament | House of Commons
- Gordon Brown, Member of Parliament | House of Commons
- Mark Adler, Member of Parliament | House of Commons
- Rick Dykstra, Member of Parliament | House of Commons
- Larry Miller, Member of Parliament | House of Commons
- Dean Allison, Member of Parliament | House of Commons
- Parm Gill, Member of Parliament | House of Commons
- Bal Gosal, Member of Parliament | House of Commons
- Terence Young, Member of Parliament | House of Commons
Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
Communication date: 2012-03-08
Posted date: 2012-04-17
Communication number: 15042-219409 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Leona Aglukkaq, Minister of Health | Health Canada (HC)
- Scott Tessier, Chief of Staff | Minister's Office | Health Canada (HC)
- Paul Glover, Assistant Deputy Minister | Health Canada (HC)
- Abby Hoffman, Assistant Deputy Minister - Strategic Policy | Health Canada (HC)
- Amanda Gordon, Executive Assistant to the Minister of Health | Minister's Office | Health Canada (HC)
Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
Communication date: 2012-03-01
Posted date: 2012-04-17
Communication number: 15042-219407 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Robert Carberry, Assistant Secretary | Regulatory Cooperation Council Secretariat | Treasury Board Of Canada Secretariat (TBS)
- Celine Duguay, Unknown | Regulatory Cooperation Council Secretariat | Treasury Board Of Canada Secretariat (TBS)
Subject Matter of the communication: Industry, Regional Development, Science and Technology, International Development
Communication date: 2012-01-31
Posted date: 2012-02-17
Communication number: 15042-208547 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Paul Glover, Assistant Deputy Minister | HPFB | Health Canada (HC)
Subject Matter of the communication: Health, Industry, Regional Development, Science and Technology, International Development
Communication date: 2012-01-31
Posted date: 2012-02-17
Communication number: 15042-208528 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Paul Glover, Assistant Deputy Minister | HPFB | Health Canada (HC)
Subject Matter of the communication: Health, Industry, Regional Development, Science and Technology, International Development
Communication date: 2012-01-30
Posted date: 2012-02-17
Communication number: 15042-208507 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Helene Marquis, Director, SRED Directorate-Ottawa | Canada Revenue Agency (CRA)
Subject Matter of the communication: Science and Technology, Taxation and Finance
Communication date: 2011-11-30
Posted date: 2011-12-16
Communication number: 15042-200651 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Dave Van Kesteren, Member of Parliament | House of Commons
Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade, Research and Development
Communication date: 2011-11-22
Posted date: 2011-12-16
Communication number: 15042-200416 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Gerald Keddy, Parliamentary Secretary to the Minister of International Trade | Foreign Affairs and International Trade Canada (DFAITC)
- Alicia Swinamer, Assistant to the Parliamentary Secretary | Foreign Affairs and International Trade Canada (DFAITC)
Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade, Research and Development
Communication date: 2011-11-17
Posted date: 2011-12-16
Communication number: 15042-200335 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Idee Inyangudor, Senior Policy Advisor | Minister's Office | Canadian International Development Agency (CIDA)
- Shuvaloy Majumdar, Policy Advisor | Minister's Office | Canadian International Development Agency (CIDA)
Subject Matter of the communication: Health, Industry, International Trade, International Development
Communication date: 2011-11-04
Posted date: 2011-12-16
Communication number: 15042-200327 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Paul Glover, Assistant Deputy Minister | Health Canada (HC)
Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
Communication date: 2011-10-18
Posted date: 2011-11-14
Communication number: 15042-194605 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Idee Inyangudor, Senior Policy Advisor | Minister of International Cooperation | Canadian International Development Agency (CIDA)
Subject Matter of the communication: Health, Industry, International Development
Communication date: 2011-08-30
Posted date: 2011-09-16
Communication number: 15042-185604 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Wladyslaw Lizon, Member of Parliament | Members of the House of Commons
Subject Matter of the communication: Health, Industry, Intellectual Property, Research and Development
Communication date: 2011-08-25
Posted date: 2011-09-16
Communication number: 15042-185584 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Alain Beaudet, President | Canadian Institutes of Health Research (CIHR)
- Jane Aubin, CSO,VP, Research and Knowledge Translation | Canadian Institutes of Health Research (CIHR)
Subject Matter of the communication: Health, Industry, Intellectual Property, Science and Technology
Communication date: 2011-07-13
Posted date: 2012-08-21
Communication number: 15042-234209 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Philip Jennings, Associate Assistant Deputy Minister | Industry Sector | Industry Canada
Subject Matter of the communication: Industry, Intellectual Property, International Trade
Communication date: 2011-06-28
Posted date: 2011-07-16
Communication number: 15042-175595 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Dave Forestell, Policy Advisor | Prime Minister's Office (PMO)
Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
Communication date: 2011-01-27
Posted date: 2011-02-16
Communication number: 15042-165589 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Tony Clement, Minister | Industry Canada
- Claude Carignan, Senator | Senate of Canada
- Richard Dicerni, Deputy Minister | Industry Canada
Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
Communication date: 2011-01-13
Posted date: 2011-02-16
Communication number: 15042-165593 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Dave Forestell, Policy Advisor | Prime Minister's Office (PMO)
Subject Matter of the communication: Industry, Intellectual Property
Communication date: 2010-08-26
Posted date: 2010-09-13
Communication number: 15042-154507 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Darren Cunningham, Chief of Staff | Minister of Industry | Industry Canada
Subject Matter of the communication: Industry, Intellectual Property
Communication date: 2010-08-26
Posted date: 2010-09-13
Communication number: 15042-154506 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Paul Wilson, Director, Policy | Prime Minister's Office (PMO)
Subject Matter of the communication: Industry, Intellectual Property
Communication date: 2010-07-16
Posted date: 2010-08-15
Communication number: 15042-153495 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Tony Clement, Minister of Industry | Industry Canada
Subject Matter of the communication: Industry, Intellectual Property
Communication date: 2010-07-14
Posted date: 2010-08-16
Communication number: 15042-153462 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Supriya Sharma, Director General | Health Canada (HC)
Subject Matter of the communication: Health
Communication date: 2010-05-28
Posted date: 2010-06-14
Communication number: 15042-150201 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Andre Paine, Director, Parliamentary Affairs | Health Canada (HC)
Subject Matter of the communication: Health
Communication date: 2010-05-19
Posted date: 2010-06-14
Communication number: 15042-150200 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Peter Van Loan, Minister of International Trade | Foreign Affairs and International Trade Canada (DFAITC)
Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade, Science and Technology
Communication date: 2010-03-10
Posted date: 2010-04-16
Communication number: 15042-146075 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Barbara Benning, Senior Executive Director | TPD | Health Canada (HC)
Subject Matter of the communication: Health
Communication date: 2009-10-19
Posted date: 2009-11-16
Communication number: 15042-128897 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Cameron Adamson, Policy Advisor | Prime Minister's Office (PMO)
Subject Matter of the communication: Health, Industry, Intellectual Property, Science and Technology, Taxation and Finance
Communication date: 2009-06-04
Posted date: 2009-07-08
Communication number: 15042-112496 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Paul Wilson, Director of Policy | Prime Minister's Office (PMO)
Subject Matter of the communication: Health, Industry
Communication date: 2009-05-27
Posted date: 2009-06-12
Communication number: 15042-109310 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Hon. Lynne Yelich, Minister of State (Western Economic Diversification) | Western Economic Diversification Canada (WD)
Subject Matter of the communication: Science and Technology
Communication date: 2009-05-27
Posted date: 2009-06-12
Communication number: 15042-109309 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Elie Salibi, Policy Advisor | Minister of Industry | Industry Canada
- Hon. Tony Clement, Minister of Industry | Industry Canada
Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade, Science and Technology, Taxation and Finance
Communication date: 2009-05-18
Posted date: 2009-06-12
Communication number: 15042-109306 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Meena Ballantyne, Assistant Deputy Minister | Health Products and Food Branch | Health Canada (HC)
Subject Matter of the communication: Health
Communication date: 2009-03-25
Posted date: 2009-04-15
Communication number: 15042-101286 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Leah Canning, Policy Advisor | Office of the Minister of Health | Health Canada (HC)
- Benoit Violette, Senior Policy Advisor | Office of the Minister of Industry | Industry Canada
- Bill King, Chief of Staff | Office of the Minister of Industry | Industry Canada
Subject Matter of the communication: Consumer Issues, Health, Industry, Intellectual Property, Science and Technology, Taxation and Finance
Communication date: 2009-01-22
Posted date: 2009-02-13
Communication number: 15042-93841 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Meena Ballantyne, Assistant Deputy Minister | Health Canada (HC)
Subject Matter of the communication: Health, Industry
Communication date: 2008-12-09
Posted date: 2009-01-16
Communication number: 15042-90173 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Amy Ringdahl, Policy Advisor | Office of the Minister of Finance | Finance Canada (FIN)
- David Rancourt, Policy Advisor | Office of the Minister of Finance | Finance Canada (FIN)
Subject Matter of the communication: Consumer Issues, Health, Industry, Intellectual Property, Science and Technology, Taxation and Finance
Communication date: 2008-12-04
Posted date: 2008-12-12
Communication number: 15042-87861 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- James Wright, High Commissioner of Canada to the United Kingdom | Foreign Affairs and International Trade Canada (DFAITC)
Subject Matter of the communication: Health, Industry, Intellectual Property, Science and Technology, Taxation and Finance
Communication date: 2008-11-21
Posted date: 2008-12-15
Communication number: 15042-88227 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Meena Ballantyne, Assistant Deputy Minister | Health Canada (HC)
Subject Matter of the communication: Health
Communication date: 2008-11-05
Posted date: 2008-12-16
Communication number: 15042-88011 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Brien Benoit, Doctor | Patented Medicine Prices Review Board (PMPRB)
Subject Matter of the communication: Consumer Issues, Health, Industry, Science and Technology
Communication date: 2008-10-21
Posted date: 2008-11-16
Communication number: 15042-84855 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- David Maloney, Assistant Deputy Minister | Industry Sector | Industry Canada
Subject Matter of the communication: Health
Communication date: 2008-08-28
Posted date: 2008-09-15
Communication number: 15042-80714 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Morris Rosenberg, Deputy Minister | Health Canada (HC)
Subject Matter of the communication: Health, Intellectual Property
Communication date: 2008-07-24
Posted date: 2008-08-16
Communication number: 15042-76909 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Suzanne Vinet, Associate Deputy Minister | Health Canada (HC)
Subject Matter of the communication: Health, Intellectual Property
Communication date: 2008-07-24
Posted date: 2008-08-16
Communication number: 15042-76141 View associated registration

Kiersten Combs, President (Corporation)

Learn more...

Results below are sorted by posted date, beginning with the most recent.

Results 1-112 of 112

AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Mark Kachuk, Special Assistant | Prime Minister's Office (PMO)
- Udita Samuel, Policy Advisor | Prime Minister's Office (PMO)
- Ben Chin, Policy Advisor | Prime Minister's Office (PMO)
Subject Matter of the communication: Health, Research and Development
Communication date: 2023-02-01
Posted date: 2023-03-17
Communication number: 15042-560351 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Shanzae Khan, Policy Advisor | Ministry of Health | Health Canada (HC)
- Sadenga Yeba, Deputy Director of Policy | Ministry of Health | Health Canada (HC)
- Jean-Sebastien Bock, Director of Policy | Office of the Minister of Health | Health Canada (HC)
Subject Matter of the communication: Research and Development, Economic Development
Communication date: 2023-01-31
Posted date: 2023-02-15
Communication number: 15042-556377 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Craoline Menard, Manager | Innovation, Science and Economic Development Canada (ISED)
- Rodrigo Arancibia, Director for Innovation, Science and Economic Development | Innovation, Science and Economic Development Canada (ISED)
Subject Matter of the communication: Economic Development
Communication date: 2023-01-26
Posted date: 2023-02-15
Communication number: 15042-556376 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Sandenga Yeba, Senior Policy Advisor | Minister's Office | Health Canada (HC)
- Jean-Sebastien Bock, Director of Policy | Office of the Minister of Health | Health Canada (HC)
- Jean-Yves Duclos, Minister of Health | Health Canada (HC)
Subject Matter of the communication: Health, Economic Development
Communication date: 2022-12-22
Posted date: 2023-01-16
Communication number: 15042-553093 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Sandenga Yeba, Senior Policy Advisor | Minister's Office | Health Canada (HC)
Subject Matter of the communication: Health, Research and Development
Communication date: 2022-11-18
Posted date: 2022-12-16
Communication number: 15042-552423 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Yash Nanda, Policy Advisor | Deputy Prime Minister's office | Finance Canada (FIN)
Subject Matter of the communication: Industry
Communication date: 2022-11-11
Posted date: 2022-12-15
Communication number: 15042-549834 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Michelle Boudreau, Executive Director | Office of Pharmaceutical Management Strategies | Health Canada (HC)
Subject Matter of the communication: Industry
Communication date: 2022-11-04
Posted date: 2022-12-15
Communication number: 15042-549833 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Darryl Patterson, Director General | Innovation, Science and Economic Development Canada (ISED)
- Kasondra White, Director General | Innovation, Science and Economic Development Canada (ISED)
Subject Matter of the communication: Industry
Communication date: 2022-10-27
Posted date: 2022-12-12
Communication number: 15042-549835 View associated registration
AstraZeneca Canada Inc.
In-house Corporation

Designated Public Office Holders who participated in the communication:
- Michelle Mujoomdar, Director, Specialty Pharmaceuticals | Strategic Policy Branch | Health Canada (HC)
- Michelle Boudreau, Executive Director, Office of Pharmaceuticals Management Strategies | Strategic Policy Branch | Health Canada (HC)
Subject Matter of the communication: Health, Research and Development
Communication date: 2022-09-28
Posted date: 2022-10-15
Communication number: 15042-543621 View associated registration

List of Public Offices Held
Position	Period Held	Last Date Designated Public Office Held
Executive Assistant and Special Assistant for Parliamentary Affairs & Communications House of Commons, Hon. Belinda Stronach, MP	August 2004 to June 2005	Not a designated office
Parliamentary Assistant House of Commons, Grant McNally, MP	July 1999 to June 2004	Not a designated office
Researcher Office of the Leader of the Opposition, Hon. Preston Manning, MP	July 1997 to July 1999	Not a designated office

List of Public Offices Held
Position	Period Held	Last Date Designated Public Office Held
Executive Assistant and Special Assistant for Parliamentary Affairs & Communications House of Commons, Hon. Belinda Stronach, MP	August 2004 to June 2005	Not a designated office
Parliamentary Assistant House of Commons, Grant McNally, MP	July 1999 to June 2004	Not a designated office
Researcher Office of the Leader of the Opposition, Hon. Preston Manning, MP	July 1997 to July 1999	Not a designated office

Date Modified:: 2022-11-22

Search and menus

Language selection

Registration - In-house Corporation

AstraZeneca Canada Inc. / Kiersten Combs, President

Registration Information

Associated Communications

Version 25 of 54 (2015-08-21 to 2015-12-21)

Version 25 of 54 (2015-08-21 to 2015-12-21)

Subject Matters

Subject Matter Details

Policies or Program

Policies or Program, Regulation

Regulation

Communication Techniques

Government Institutions

Description of activities

Responsible officer name and position during the period of this registration

Government funding

In-house Corporation Contact Information

Parent Company Information

Subsidiary Beneficiary Information

List of Senior Officers whose lobbying activities represent less than 20% of their Duties

List of Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties